Login / Signup

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study.

Marc HumbertPaul M HassounKelly M ChinGuillermo BortmanMahesh J PatelCarmen La RosaWei FuMaria José LoureiroMarius M Hoeper
Published in: The European respiratory journal (2024)
In participants with PAH on stable background therapy, including PDE5i, inhaled MK-5475 reduced PVR and was well tolerated, without evidence of systemic side-effects such as hypotension, suggesting a pulmonary selective pharmacodynamic effect.
Keyphrases
  • pulmonary arterial hypertension
  • pulmonary hypertension
  • pulmonary artery
  • cystic fibrosis
  • polycyclic aromatic hydrocarbons
  • coronary artery
  • mesenchymal stem cells
  • combination therapy